Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (Mylovenge™), given after ASCT for MM. We compared the results with that of other patients with MM...

詳細記述

保存先:
書誌詳細
主要な著者: Lacy, Martha Q., Mandrekar, Sumithra, Dispenzieri, Angela, Hayman, Suzanne, Kumar, Shaji, Buadi, Francis, Dingli, David, Litzow, Mark, Wettstein, Peter, Padley, Douglas, Kabat, Brian, Gastineau, Dennis, Rajkumar, S. Vincent, Gertz, Morie A.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2908015/
https://ncbi.nlm.nih.gov/pubmed/19899131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21560
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料